Home

If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk

overview

SMi is proud to present the 3rd Annual Injectable Drug Delivery Virtual Conference on 12th and 13th May 2021.


Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, innovations in device design, quality management and connectivity for enhanced subcutaneous delivery.

With rapid developments in the parenteral space the injectable drug delivery market is set to reach USD 902.3 billion by 2027, with an increased focus on patient centricity during DDC development, innovations in device development, including and new therapeutic applications including the delivery of siRNA - this year’s event will focus on advances in drug product formulation and innovations of device design and development to aid delivery. 

Furthermore, this year’s event will assess the evolving regulatory environment of injectable drug delivery with industry and regulatory representatives presenting updates on current guidelines.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Device Testing Managers, Senior Device Engineers, Heads of Device Development, Heads of Formulation and Drug Process Development, and many more.
 


 

  • DELVE into the latest work in complex formulation for subcutaneous delivery
  • BENCHMARK against leading pharma companies working to enhance device design and development
  • UNDERSTAND the regulatory environment of the injectables space from leading regulatory and industry advisors
  • ENGAGE in industry case studies on design controls, human factors and parenteral formulation
  • EXPLORE advances in connectivity and human factors key learnings in two pre-conference workshops
     

 

 Executives, Directors, VPs, Heads, Principals, Managers, Scientists, Researchers of:
• Autoinjectors
• Wearables
• Device Engineering
• Human Factors
• CMC
• Injectables
• Sterile Manufacturing
• Packaging
• Regulatory Affairs

Allergan; Almac Group; Bespak Europe Ltdá; Cambridge Design Partnership; Camurus AB; Covestro Deutschland AG; Credence MedSystems, Inc.; Crux Product Design, Ltd; Enable Injections; Eveon; Evonik Corporation; Full Spectrum Innovation Ltd; GlaxoSmithKline Biologicals S.A; GSK; Harvey Medical Consulting Ltd; Human Factors Centre Ltd; Inspired Usability; Janssen Supply Chain, Johnson & Johnson; Luto; MedinCell; Merck Serono S.A.; MHRA; Novartis Pharma AG; Owen Mumford; PA Consulting; Rebus Medical Ltd; SABIC; Sanofi; SMi Group Ltd; Team Medical Devices; TEN; UCB; UCL School of Pharmacy; Ypsomed; Zentiva, k.s.;

Conference programme

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Alexander Zuern

Alexander Zuern, Device testing manager, Novartis International AG

9:10 A regulatory outlook of the Drug/Device Combinations (DDC) products space - Session Reserved for the MHRA

Session Reserved for MHRA

Session Reserved for MHRA, ,

  • An overview on the MHRA guidelines for Drug Device Combination products
  • An update on the EU MDR and guidance for industry
  • A future regulatory outlook for the injectable drug delivery space
     
  • 9:50 Regulatory requirements for – Medicinal product incorporating a drug delivery device component in context with EU MDR

    Vikas Jaitely

    Vikas Jaitely , Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

  • Integral delivery systems for injectable drugs and what changes in context with EU MDR
  • Regulatory requirements to support registration of single integral medicinal product containing a drug delivery device component
  • How an end-to-end approach to drug product control, acceptable PQS and an appropriate risk profile can minimize the need for wholly on end product testing
  • Connected Health technologies in delivery of injectable drugs – future outlook
     
  • 10:30 Morning Coffee

    11:00 Beyond Article 117

    Blake Green

    Blake Green, Senior Manager Regulatory Affairs, Amgen
    View Bio

  • Perspective: Annex I to Directive 2001/83/EC, point 12 of Section 3.2
  • Is the bar higher for Notified Body Opinions?
  • Co-packaging implications for Importers and Distributors
  • Co-packaging implications for the MAH
  • Clinical evaluation of prefilled devices
     
  • 11:40 Advanced modalities and formulation in the injectable space

    Tina Arien

    Tina Arien, Principal Scientist, Janssen Pharmaceutica
    View Bio

  • An overview of the current requirements effecting injectable drug product formulation
  • Challenges in high viscosity and high concentration formulation for injectables
  • Advances for injectable delivery >2ml and industry considerations
  • Challenges in development of injectable oligonucleotide therapies
     
  • 12:20 Networking Lunch

    13:20 Challenges for development of long acting injectables: focus on formulations of fragile molecules

    Joel Richard

    Joel Richard, Head of Technical & Pharmaceutical Operations, MedinCell
    View Bio

  • Successful technologies for long acting injectables and their limitations
  • Competitive advantages of injectable in situ forming implant technologies
  • Specific formulation challenges for fragile molecules (peptides and proteins)
  • Recent progress from BEPO® long acting injectable formulation development
     
  • 14:00 A study to investigate an acceptable flow rate for large volume subcutaneous injections in healthy volunteers

    Mark Palmer

    Mark Palmer, Scientific Leader, Biopharm Device Engineering, GSK
    View Bio

  • Autoinjectors are commonly used for subcutaneous delivery of volumes of up to 1ml in around 10s while larger volumes may be delivered by wearable devices over tens of minutes
  • In this study we targeted subcutaneous delivery of up to 5ml of saline in 3 to 1.2 minutes
  • Acceptability was assessed by questionnaire and by Visual Analog Scale (VAS) pain scores
     
  • 14:40 CMC challenges of formulation and drug product development of biologics

    Camille Dagallier

    Camille Dagallier, Formulation and Drug Process Development Senior Scientist, Sanofi

  • Challenges with high concentration, high viscosity and large volume drug products
  • In-use studies for subcutaneous administration
  • Trends to overcome current challenges in injectable biologics space
     
  • 15:20 Afternoon Tea

    15:50 Designing Instructions for Use (IFU) guided by human factors

  • Human Factors principals of IFU design
  • FDA guidance on IFU design
  • Real-world IFU examples, including FDA feedback received on IFUs
  • Kimberley Alexander

    Kimberley Alexander, Associate, Core Human Factors

    Steve Beighley

    Steve Beighley, Associate, Core Human Factors

    16:30 Opportunities and challenges in delivering strategic platforms for injectable drug products

    Stefano Martini

    Stefano Martini, Responsible for Special Programs, Medical Devices Development,
    View Bio

  • Platform approach in designing and developing DDCS
  • Purchasing control and supplier relationship considerations for a successful platform approach 
  • Challenges in developing injectable platforms for novel drug products
  • Case studies leveraging platforms for parenteral drugs
  • How enhanced supplier relationship and purchasing control can result in a win-win project for all teams
  • 17:10 Chair’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chair's Opening Remarks

    Alexander Zuern

    Alexander Zuern, Device testing manager, Novartis International AG

    9:10 Getting ready for EMA post 2020 regulatory environment for drug-device combination products – A case study of EU MDR Art 117 implementation

    Bjorg K Hunter

    Bjorg K Hunter, Regulatory Manager, Devices, GSK
    View Bio

  • Submission of medicines including a device component in the EU post May 2020 are changing in accordance with EU MDR Art 117 and EU draft guidelines on quality aspects of a drug-device combination
  • Overview of what the changes means for pharma companies in ways of working
  • Areas of uncertainty which comes with these new ways of working
  • Examples of how the new requirements can be implemented
  • 9:50 Notified Bodies and Article 117

    Jonathan Sutch

    Jonathan Sutch, Medicinal Specialist, BSI Group
    View Bio

  • Notified Bodies and Drug Device Combinations
  • BSI’s experience with Article 117 applications
  • Documentation from the manufacturer
  • Notified Body Opinion Report
  • 10:30 Morning Coffee

    11:00 Life cycle management and post market changes for injectable devices

    Amanda Matthews

    Amanda Matthews, Senior Director, Pfizer UK Limited

  • How pharma companies are going to adapt to Article 117 of the EU MDR
  • Current status and expectations from an industry perspective
  • Changes that might trigger the need for a Notified Body Opinion
     
  • 11:40 LNP™ material solutions addressing the needs for the circular economy in the medical industry

    Alexander Fix

    Alexander Fix, Business Development Leader, SABIC
    View Bio

  • Why sustainability should matter us
  • Overview about technology options for more sustainable polymer solutions
  • From a discarded PET bottle to a PBT polymer: LNP™ ELCRIN™ iQ resin (PBT)
     
  • 12:20 Silicone Oil free pre-filled syringes (PFS) - Part of the future?

    Christian Dechant

    Christian Dechant, Director Primary Packaging & Process Development, Boehringer Ingelheim GmbH & Co. KG
    View Bio

  • Advantages of silicone oil free prefilled syringes
  • Points that have to be considered in drug development from the beginning, e.g. compatibility of formulation and primary packaging materials
  • Overview of potential new technologies to select a silicone oil free prefilled syringe system 
  • 13:00 Networking Lunch

    14:00 Click sound characterization of autoinjectors

    Alexander Zuern

    Alexander Zuern, Device testing manager, Novartis International AG

  • Different devices were characterized on the frequencies and loudness of click sounds
  • A correlation between the click sounds and other parameters such as activation force were made
  • Homogeneity of click sounds were characterized
  • 14:40 Design Control in Combination Products

    Rupal Nguyen

    Rupal Nguyen, Consultant, R&D - Device and Combination Products, Allergan
    View Bio

  • Combination product development bridges (Pharma/Biologics - Device) 
  • Early stage consideration during combination product development
  • Combination product development process (from early phase to manufacturing transfer)
  • Case study – Combination products
  • Challenges
     
  • 15:20 Afternoon Tea

    15:50 Friction and Fracture: how science can improve patients' quality life

    Cinzia Rotella

    Cinzia Rotella, Senior Materials Scientist, Sanofi
    View Bio

  • Identify areas where scientific gaps prevents sound design engineering of DDC
  • Case studies on using fundamental science to:
  • Rigorously define system requirements
  • Determine the appropriate control plans for robust manufacturing of DDC (PFS, Autoinjector, pen, …)
  • 16:30 To connect or not to connect: When should a parenteral device go connected?

    Paul Greenhalgh

    Paul Greenhalgh, Director of Design, Team Consulting
    View Bio

  • What is the problem you are trying to solve?
  • What does adding sensing really mean?
  • Don’t ignore the human factor!
     
  • 17:10 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Alexander Fix

    Alexander Fix

    Business Development Leader, SABIC
    Alexander Zuern

    Alexander Zuern

    Device testing manager, Novartis International AG
    Bjorg K Hunter

    Bjorg K Hunter

    Regulatory Manager, Devices, GSK
    Blake Green

    Blake Green

    Senior Manager Regulatory Affairs, Amgen
    Camille Dagallier

    Camille Dagallier

    Formulation and Drug Process Development Senior Scientist, Sanofi
    Christian Dechant

    Christian Dechant

    Director Primary Packaging & Process Development, Boehringer Ingelheim GmbH & Co. KG
    Cinzia Rotella

    Cinzia Rotella

    Senior Materials Scientist, Sanofi
    Joel Richard

    Joel Richard

    Head of Technical & Pharmaceutical Operations, MedinCell
    Jonathan Sutch

    Jonathan Sutch

    Medicinal Specialist, BSI Group
    Kimberley Alexander

    Kimberley Alexander

    Associate, Core Human Factors
    Mark Palmer

    Mark Palmer

    Scientific Leader, Biopharm Device Engineering, GSK
    Paul Greenhalgh

    Paul Greenhalgh

    Director of Design, Team Consulting
    Rupal Nguyen

    Rupal Nguyen

    Consultant, R&D - Device and Combination Products, Allergan
    Stefano Martini

    Stefano Martini

    Responsible for Special Programs, Medical Devices Development,
    Steve Beighley

    Steve Beighley

    Associate, Core Human Factors
    Tina Arien

    Tina Arien

    Principal Scientist, Janssen Pharmaceutica
    Vikas Jaitely

    Vikas Jaitely

    Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck

    Alexander Fix

    Business Development Leader, SABIC
    Alexander Fix

    Alexander Fix is a Business Development Leader in the global healthcare organization at SABIC. He has been with SABIC for 5 years and has held different roles in Account Management and Marketing. As a Business Development Leader, Alexander focuses on the development of material solutions for drug delivery devices and works closely with customers to provide technical support for their application development.
    He holds a diploma in Business Administration from AKAD private University in Stuttgart, Germany.
     

    Alexander Zuern

    Device testing manager, Novartis International AG
    Alexander Zuern

    Amanda Matthews

    Senior Director, Pfizer UK Limited
    Amanda Matthews

    Amanda Matthews

    Senior Director, Pfizer UK Limited
    Amanda Matthews

    Bjorg K Hunter

    Regulatory Manager, Devices, GSK
    Bjorg K Hunter

    Bjorg Hunter holds a BSc in Design and Innovation Engineering from Technical University of Denmark and an MSc in Biomedical Engineering from Aarhus University, Denmark. Bjorg has been with GSK since graduating and has held different roles within the Device Engineering Group. In 2015 Bjorg moved into the late stage parenterals area as device lead for key GSK parenteral devices, working closely with internal GSK project teams and external partners including device development, Human Factors and regulatory compliance. She progressed into leading a device management team in January 2017, where she has had the accountability of project management and regulatory compliance for parenteral devices. In February 2019 Bjorg moved into a key management role in CMC regulatory where she is responsible for the global regulatory and advocacy strategy for GSK’s portfolio of devices across modalities and lifecycle.

    Blake Green

    Senior Manager Regulatory Affairs, Amgen
    Blake Green

    Blake Green is a Regulatory Affairs Senior Manager with Amgen’s Global Medical Devices Regulatory team. Based in Cambridge UK. Blake is a Devices Regulatory lead for medicinal product/medical device combination products and co-packaged medical devices in the biopharmaceutical sector. Prior to joining Amgen, Blake had significant international experience securing multi-national market clearance for manufacturers of medical devices, medical device/medicinal product combinations, medical software, personal protective equipment, and biocides, located throughout the United States of America, European Union, North Africa, Middle East, Far East, Turkey, Israel, Australia, Canada, and Peoples Republic of China.

    Camille Dagallier

    Formulation and Drug Process Development Senior Scientist, Sanofi
    Camille Dagallier

    Christian Dechant

    Director Primary Packaging & Process Development, Boehringer Ingelheim GmbH & Co. KG
    Christian Dechant

    Christian Dechant
    Director Primary Packaging Development Biologicals
    Pharmaceutical Development Biologicals
    Boehringer Ingelheim Pharma GmbH&Co. KG


    Christian Dechant brings more than 19 years experience in various roles to the primary packaging development at Boehringer Ingelheim.
    At BI microParts GmbH he started working in research & development of microfluidic systems and was later responsible for the implementation and running of clinical trial manufacturing for Devices (e.g. Respimat)
    In 2010 he starts working at Boehringer Ingelheim as a primary packaging engineer with focus on liquid formulations for parenteral and oral solutions. Since 2014 he is responsible for the primary packaging development group for parenteral solution within Pharmaceutical Development Biologicals. He established the primary packaging development group with focus on NCE and NBE development. In this role he is responsible for the selection of suitable container closure systems to ensure the stability of the formulation and the functionality within a combination product like an autoinjector.
    Christian Dechant holds a Diploma degree in industrial engineering from the University of Applied Sciences of Bochum, Germany.
     

    Cinzia Rotella

    Senior Materials Scientist, Sanofi
    Cinzia Rotella

    I am in charge of the Material Lab. and of developing new methods to characterize materials. I am also responsible of projects related to rubber tribology and to the mechanical properties of glass primary containers.

    I joined Sanofi in 2016

    Before then
    2012-2015 – Postdoctoral fellow at ESPCI Paris –Rheology of innovative polymer materials

    2007-2011 – PhD in Physics at KULeuven – Glass transition of confined polymers probed by spectroscopy

    2006 – Master in Materials Science, UNIPI – Polymer science
     

    Joel Richard

    Head of Technical & Pharmaceutical Operations, MedinCell
    Joel Richard

    Dr Joël Richard is currently Executive Committee Member and Head of Technical & Pharmaceutical Operations at MedinCell (Montpellier, France). He is leading all the development activities of the company, based on the proprietary technology BEPO® for Long-Acting Injectables. (LAIs). These activities comprise formulation and process development, device development, analytical development, process transfer and scale-up, manufacturing and supply of clinical batches, regulatory affairs and clinical development operations, quality and regulatory compliance. Dr Richard has more than 30 years of experience in chemistry and (bio)pharmaceutical R&D, including several global senior leadership positions in various Biotech and Pharma companies, such as Ipsen (France), Serono (Italy), MerckSerono (Germany), Ethypharm (France). Dr Richard has focused his research activity on new formulation technologies and innovative drug delivery systems (microspheres, nanosystems, self-assembling gels), especially for injectable peptide and protein formulations. He has graduated from Ecole Normale Supérieure (Cachan, France), and got a PhD in Materials Science (Paris VI, France), and the “Habilitation à Diriger les Recherches” in Chemistry (Bordeaux I, France). He has published 69 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields. He is the author of 140 international communications and 55 patent families. He has also been serving as an APGI Board Member for 3 years and is a Member of the Controlled Release Society (CRS).

    Jonathan Sutch

    Medicinal Specialist, BSI Group
    Jonathan Sutch

    Dr Jonathan Sutch is a medicinal specialist at the Notified Body BSI Group, working with medical devices containing medicinal substances and drug/device combinations. Jon trained as a Pharmacist at the London School of Pharmacy prior to completing a PhD in Pharmaceutical Sciences at Nottingham University. He has 15 years of experience in the pharmaceutical industry as a formulation scientist and manager before moving to BSI 2 years ago.

    Kimberley Alexander

    Associate, Core Human Factors
    Kimberley Alexander

    Mark Palmer

    Scientific Leader, Biopharm Device Engineering, GSK
    Mark Palmer

    Dr. Mark Palmer is currently a member of the Device Engineering group at GlaxoSmithKline and has worked on a variety of inhaled, intranasal, ophthalmic and parenteral drug delivery devices. Dr Palmer holds PhD from Cranfield University, an MSc in Engineering Design and a BSc in Physics.

    Paul Greenhalgh

    Director of Design, Team Consulting
    Paul Greenhalgh

    Paul leads Design and Innovation at Team, (based in Cambridge UK). Working closely with clients and colleagues to improve the user experience of medical devices, through carefully crafted industrial design, digital UI/UX, packaging and information design solutions.
    With over 20 years’ experience helping companies bring innovative, user centred products into reality, Paul focuses on helping clients at the front end of development, to set the right direction and ensure user, commercial and technical needs are thoroughly understood.
    His recent involvement in a number of early stage device programmes has reinforced Paul’s belief that the adoption of design thinking not only results in great products but helps to overcome many of the challenges that project teams face during the early stages of development.
     

    Rupal Nguyen

    Consultant, R&D - Device and Combination Products, Allergan
    Rupal Nguyen

    Rupal Nguyen is a Mechanical Engineer in the R&D Department of medical device & Pharma Industries. Currently, she works at Allergan as a consultant and responsible for developing medical devices and combination products. She holds Ph.D. and master’s degree in applied mathematics and mechanical engineering respectively. She also holds executive MBA certification from UCI, California. She has 17+ years of experience in Medical device industries. Her areas of expertise are advanced R&D - to convert concept into functional prototypes, in-vivo and in-vitro testing, Design Controls and Human Factors Engineering. For over 8 years, she has worked primarily in advanced R&D of neuro and peripheral implantable medical devices and combination products portfolio. She holds multiple patents related to implantable medical devices and delivery systems.

    Session Reserved for MHRA

    ,
    Session Reserved for MHRA

    Stefano Martini

    Responsible for Special Programs, Medical Devices Development,
    Stefano Martini

    I joined Sanofi France, on June 2016 in Medical Devices Development – Primary Component (PCD) initially as Responsible of External Projects (June 2016-March 2018), then as Head of Operations of PC Early Stage and Platform Development (April 2018-June 2020) and since then as Responsible of Special Programs.

    Over the last 30+ years I have gained a huge knowledge about PC development, working from 2013 to 2016 as Responsible of the Primary Component Forensic Characterisation laboratory at Amgen LTD in Ireland - Dublin and before then, for 20+ years, at Stevanato Group in several managerial position in both operations and process development for ampoules, vials and PFS.

    I hold a BSc in Pharmaceutical Technologies from TU Dublin and a Lean Six Sigma Black Belt certification from Festo Italy.

    Steve Beighley

    Associate, Core Human Factors
    Steve Beighley

    Tina Arien

    Principal Scientist, Janssen Pharmaceutica
    Tina Arien

    Albertina Ariën, works since 1998 at Janssen Pharmaceutica in Belgium where she held various positions in the Pharmaceutical Sciences and Drug Product Development (DPD) organization. Currently she works as a principal scientist in the Parenterals and Liquids group of DPD and is expert in the development of complex injectable formulations and pediatric dosage forms. Dr Ariën holds a degree in biochemical engineering from Katholieke Hogeschool Limburg, Belgium and a PhD in Biomedical Sciences from the University of Bordeaux, France. She spent 2 years as a post-doc at the University of Nottingham, UK where she did research on polymeric nanotechnology.

    Vikas Jaitely

    Director, Global Regulatory Affairs Transitional Medicine and Devices, Merck
    Vikas Jaitely

    Official Media Partner

    Key Media Partners

    Supporters

    Workshops

    Developing Apps for Connected Drug Delivery Devices - a practical and integrated HF approach
    Workshop

    Developing Apps for Connected Drug Delivery Devices - a practical and integrated HF approach

    Online Virtual Event
    11th May 2021
    Online Virtual Event , United Kingdom

    VENUE

    Online Virtual Event

    Online Virtual Event , Online Virtual Event , United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Speaker interview with Joel Richard, MedinCell

    Download

    Brochure 2020

    Download

    Paul Greenhalgh, Director of Design, Team Consulting

    Download

    Workshop Programme

    Download

    Speaker Interview - Julian Dixon, Team Consulting

    Download

    Speaker Interview - Ben Cox, Team Consulting

    Download

    Speaker Biographies

    Download

    Past Attendees

    Download

    Current Programme

    Download

    Presentation by Tom Fussey, Cambridge Design Partnership

    Download

    Presentation by Stephen Paboojian, Novartis

    Download

    Presentation by Sigrid Van Dyck, Janssen

    Download

    Presentation by Quentin Le Masne, Merck

    Download

    Presentation by Miranda Newberry and Louisa Harvey, MHFN

    Download

    Presentation by Mark Hassett, Credence Medsystems

    Download

    Presentation by Joel Richard, MedinCell

    Download

    Presentation by Edward Sims, Crux Product Design

    Download

    Presentation by Adeline Meilhoc, Eveon

    Download

    Media Partners


    Pharma Journalist

    Official Media Partner
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    ONdrugDelivery Magazine

    Official Media Partner
    http://ondrugdelivery.com

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.

    Media Partners


    pharmaphorum

    Key Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    pharmanews hq

    Key Media Partners
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    World Pharma News

    Key Media Partners
    http://www.worldpharmanews.com/



    Pharmaceutical Technology

    Key Media Partners
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    International Pharmaceutical Industry (IPI)

    Key Media Partners
    http://ipimediaworld.com/

    IPI – International Pharmaceutical Industry IPI – was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally. Edited by our carefully selected editorial advisory panel, and extensive research network, IPI provides a proven supportive means of communication to the pharmaceutical, bio pharmaceutical, nutraceutical and medical devices industry the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies which will enable them to be more efficient, bring products to market faster, reduce cost and make healthcare accessible to all.

    Media Partners


    Technology Networks

    Supporters
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out